This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary and join the 2,487 subscribers getting it for FREE every day!
FEBRUARY 27, 2020
STOCKS: ACAD, BABA, MU, AMD, SQ
MARCO: SPY, GOLD, EWG, EWY
MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN ACAD
Stocks are pointing to some more losses this morning, with the S&P 500 futures down to about 3,100, with support on the futures around 3,080. Like I have said, it seems that the 3,110 region appears to be the creation of a bottoming process, and so far, we are still hanging around this region.
The S&P 500 fell to around 3,115 on February 25, 3110, on the 26, and about 3,100 today. So It creates this 15 point region where it seems that at least declines have slowed. So that is roughly a 75 basis point region, and that tends to be how I approach things, looking for regions.
Anyway, this is how it looks on the daily change of the S&P 500.
You can see this same type of zone that has formed on the Kospi, which is about 1% wide and is an essential level of support around 2,061 that dates back to mid-October.
Again, you can see the same in the DAX, which is also at an essential level of support at its October break out around 12,500.
Gold prices have hardly moved, and that seems odd to me.
So we can wait and see what happens, nobody has a clue what will happen or when it will end. I’ll probably be proven wrong too, because I’m trying to think in a logical sense, while markets operate in an illogical sense.
I thought Acadia is starting to show some strong momentum on Nuplazid sales, and in a normal environment, the stock should trade higher. The company noted on the call that Nuplazid could get an approval in DRP before year-end, due to its breakthrough therapy designation. So will the stock rise? I hope it does; it deserves too. But trying to figure out where this stock goes in a normal trading session is hard enough, let alone in this environment.
Alibaba continues to rebound and rise in this environment, which seems unusual. But $211 has been acting as resistance so that it if can clear $211, then perhaps it can move on to $220. If not, back to $200.
AMD is sitting on a support level at $46.80, and that level of support has been firm for some time. This level needs to hold for AMD, or it declines to $43.
Square is trading at resistance at $83 following its results, and this may not be a day for the stock to break resistance.
Micron is falling some but holding support, and yesterday I noted that I was seeing some bullish betting that shares recover by April. Free – Micron’s Stock May Not Stay Down For Long
My throat is hurting today, ugh.
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.